NIFTY 50

Relief for Sun Pharma: SEBI finds no merit in fraud allegations

Updated : August 29, 2019 08:06 AM IST

Sun Pharmaceutical Industries will be in focus today following reports the Securities and Exchange Board of India (SEBI) has found no merit in the allegations of fraud against the company.

The Sebi conducted inquiry following the allegations of corporate governance and tax-related offences by a whistle-blower against Sun Pharmaceutical.

Sebi had sought answers on two queries – one was the fund diversion of Rs 42,000 crore through the subsidiary Aditya Medisales and second was the 2004 fundraising through the foreign currency convertible bond (FCCB) route.

According to a report, the alleged fund diversion never generated huge profits.

CNBC-TV18 has not verified the report independently and cannot vouch for its authenticity.
primo org
Have you signed up for Primo, our daily newsletter?
It has all the stories and data on the market, business, economy and tech that you need to know.
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more
Live TV